Across TCGA pan-cancer cohorts, SELENOH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SELENOH data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SELENOH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SELENOH expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where SELENOH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	1.000	0.185	.008	40	view →
CCRCC	OS	Quartile	All	1.000	0.574	.007	19	view →
LUAD	OS	Tertile	II,III,IV	0.871	0.326	.021	13	view →
GBM	OS	Quartile	All	0.611	0.308	.028	2	view →
PDAC	DFS	Quartile	All	0.825	0.683	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SELENOH tumor-vs-normal RNA expression · all SELENOH data types